Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Sankyo Aiming for 50% Market Share through Mevalotin, Livalo
September 29, 2003
- Chuikyo Committee Approves Draft Questionnaire on New Medical Technologies
September 29, 2003
- Dear-Doctor Letter Ordered for Intestinal Cleanser Niflec
September 29, 2003
- Hepatitis C Found in 1.6% of People Screened: Survey
September 29, 2003
- REGULATORY NEWS IN BRIEF
September 29, 2003
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
September 29, 2003
- NEW PRODUCTS
September 29, 2003
- Nihon Schering Establishing New Research Center in Kobe
September 29, 2003
- Meet the Leaders (25)
September 29, 2003
- Kurume Univ. to Begin Course in Biostatistics
September 29, 2003
- Teva Submits NDA for MAO-B Inhibitor to FDA: Alliance with Eisai
September 22, 2003
- Smoking Increases Medical Costs for COPD: NBI
September 22, 2003
- FDA Approves New Indication for Abilify from BMS, Otsuka
September 22, 2003
- Tanabe Applies for Approval of Research Using Human ES Cells
September 22, 2003
- Alfressa Aims to Be No. 1 Wholesaler with \2 Tril. Sales by 2008
September 22, 2003
- Pathological Aging Must Be Overcome to Achieve Longevity: JPLA Seminar
September 22, 2003
- BUSINESS NEWS IN BRIEF
September 22, 2003
- PRESS SEMINAR
September 22, 2003
- Laserphyrin, Prodif Recommended for Approval
September 22, 2003
- RESEARCH & DEVELOPMENT NEWS IN BRIEF
September 22, 2003
ページ
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…